Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors

The use of antibody-based therapeutics has proven very promising for clinical applications in cancer patients, with multiple examples of antibodies and antibody–drug conjugates successfully applied for the treatment of solid tumors and lymphomas. Given reported recurrence rates, improvements are cle...

Full description

Bibliographic Details
Main Authors: Katerina T. Xenaki, Sabrina Oliveira, Paul M. P. van Bergen en Henegouwen
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-10-01
Series:Frontiers in Immunology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2017.01287/full
id doaj-bda872ec99b64d89a370db1dcdee3b4c
record_format Article
spelling doaj-bda872ec99b64d89a370db1dcdee3b4c2020-11-24T20:41:19ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-10-01810.3389/fimmu.2017.01287291765Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid TumorsKaterina T. Xenaki0Sabrina Oliveira1Sabrina Oliveira2Paul M. P. van Bergen en Henegouwen3Division of Cell Biology, Science Faculty, Department of Biology, Utrecht University, Utrecht, NetherlandsDivision of Cell Biology, Science Faculty, Department of Biology, Utrecht University, Utrecht, NetherlandsPharmaceutics, Department of Pharmaceutical Sciences, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, NetherlandsDivision of Cell Biology, Science Faculty, Department of Biology, Utrecht University, Utrecht, NetherlandsThe use of antibody-based therapeutics has proven very promising for clinical applications in cancer patients, with multiple examples of antibodies and antibody–drug conjugates successfully applied for the treatment of solid tumors and lymphomas. Given reported recurrence rates, improvements are clearly still necessary. A major factor limiting the efficacy of antibody-targeted cancer therapies may be the incomplete penetration of the antibody or antibody–drug conjugate into the tumor. Incomplete tumor penetration also affects the outcome of molecular imaging, when using such targeting agents. From the injection site until they arrive inside the tumor, targeting molecules are faced with several barriers that impact intratumoral distribution. The primary means of antibody transport inside tumors is based on diffusion. The diffusive penetration inside the tumor is influenced by both antibody properties, such as size and binding affinity, as well as tumor properties, such as microenvironment, vascularization, and targeted antigen availability. Engineering smaller antibody fragments has shown to improve the rate of tumor uptake and intratumoral distribution. However, it is often accompanied by more rapid clearance from the body and in several cases also by inherent destabilization and reduction of the binding affinity of the antibody. In this perspective, we discuss different cancer targeting approaches based on antibodies or their fragments. We carefully consider how their size and binding properties influence their intratumoral uptake and distribution, and how this may affect cancer imaging and therapy of solid tumors.http://journal.frontiersin.org/article/10.3389/fimmu.2017.01287/fullmolecular imagingcancer therapyantibodyantibody fragmentssingle-domain antibodiesnanobody
collection DOAJ
language English
format Article
sources DOAJ
author Katerina T. Xenaki
Sabrina Oliveira
Sabrina Oliveira
Paul M. P. van Bergen en Henegouwen
spellingShingle Katerina T. Xenaki
Sabrina Oliveira
Sabrina Oliveira
Paul M. P. van Bergen en Henegouwen
Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors
Frontiers in Immunology
molecular imaging
cancer therapy
antibody
antibody fragments
single-domain antibodies
nanobody
author_facet Katerina T. Xenaki
Sabrina Oliveira
Sabrina Oliveira
Paul M. P. van Bergen en Henegouwen
author_sort Katerina T. Xenaki
title Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors
title_short Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors
title_full Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors
title_fullStr Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors
title_full_unstemmed Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors
title_sort antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2017-10-01
description The use of antibody-based therapeutics has proven very promising for clinical applications in cancer patients, with multiple examples of antibodies and antibody–drug conjugates successfully applied for the treatment of solid tumors and lymphomas. Given reported recurrence rates, improvements are clearly still necessary. A major factor limiting the efficacy of antibody-targeted cancer therapies may be the incomplete penetration of the antibody or antibody–drug conjugate into the tumor. Incomplete tumor penetration also affects the outcome of molecular imaging, when using such targeting agents. From the injection site until they arrive inside the tumor, targeting molecules are faced with several barriers that impact intratumoral distribution. The primary means of antibody transport inside tumors is based on diffusion. The diffusive penetration inside the tumor is influenced by both antibody properties, such as size and binding affinity, as well as tumor properties, such as microenvironment, vascularization, and targeted antigen availability. Engineering smaller antibody fragments has shown to improve the rate of tumor uptake and intratumoral distribution. However, it is often accompanied by more rapid clearance from the body and in several cases also by inherent destabilization and reduction of the binding affinity of the antibody. In this perspective, we discuss different cancer targeting approaches based on antibodies or their fragments. We carefully consider how their size and binding properties influence their intratumoral uptake and distribution, and how this may affect cancer imaging and therapy of solid tumors.
topic molecular imaging
cancer therapy
antibody
antibody fragments
single-domain antibodies
nanobody
url http://journal.frontiersin.org/article/10.3389/fimmu.2017.01287/full
work_keys_str_mv AT katerinatxenaki antibodyorantibodyfragmentsimplicationsformolecularimagingandtargetedtherapyofsolidtumors
AT sabrinaoliveira antibodyorantibodyfragmentsimplicationsformolecularimagingandtargetedtherapyofsolidtumors
AT sabrinaoliveira antibodyorantibodyfragmentsimplicationsformolecularimagingandtargetedtherapyofsolidtumors
AT paulmpvanbergenenhenegouwen antibodyorantibodyfragmentsimplicationsformolecularimagingandtargetedtherapyofsolidtumors
_version_ 1716825578032594944